# A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects

> **NCT05942625** · PHASE1 · RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 84 (estimated)

## Conditions studied

- IgA Nephropathy
- Focal Segmental Glomerulosclerosis

## Interventions

- **DRUG:** HS-10390 tablet
- **DRUG:** Placebo tablet

## Key facts

- **NCT ID:** NCT05942625
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-23
- **Primary completion:** 2024-06-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2024-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05942625

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05942625, "A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05942625. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*